Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (21-30 of 315) with videos related to

Pageof 32
Sort By:
Advances in Cancer Research|December 13, 2006
Pharmacodynamic biomarkers for molecular cancer therapeuticsDebashis Sarker, Paul Workman
Nature|April 9, 2010
Cancer: drug-tolerant insurgentsPaul Workman, Jon Travers
Cancer Cell|July 12, 2017
Choose and Use Your Chemical Probe Wisely to Explore Cancer BiologyJulian Blagg, Paul Workman
Expert Opinion on Biological Therapy|January 5, 2002
HSP90 as a new therapeutic target for cancer therapy: the story unfoldsAlison Maloney, Paul Workman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
Hsp90 molecular chaperone inhibitors: are we there yet?Len Neckers, Paul Workman
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
PI3 Kinase in Cancer: From Biology to ClinicPaul Workman, Paul Clarke
Chemistry & Biology|July 9, 2010
Probing the probes: fitness factors for small molecule toolsPaul Workman, Ian Collins
Nature Chemical Biology|November 17, 2006
New approaches to molecular cancer therapeuticsIan Collins, Paul Workman
Current Opinion in Pharmacology|September 2, 2014
Chemical biology approaches to target validation in cancerJulian Blagg, Paul Workman
Seminars in Oncology|September 25, 2016
Critical parameters in targeted drug development: the pharmacological audit trailUdai Banerji, Paul Workman
Pageof 32

Showing results (21-30 of 315) with videos related to

Sort By:
Pageof 32
Advances in Cancer Research|December 13, 2006
Pharmacodynamic biomarkers for molecular cancer therapeuticsDebashis Sarker, Paul Workman
Nature|April 9, 2010
Cancer: drug-tolerant insurgentsPaul Workman, Jon Travers
Cancer Cell|July 12, 2017
Choose and Use Your Chemical Probe Wisely to Explore Cancer BiologyJulian Blagg, Paul Workman
Expert Opinion on Biological Therapy|January 5, 2002
HSP90 as a new therapeutic target for cancer therapy: the story unfoldsAlison Maloney, Paul Workman
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
Hsp90 molecular chaperone inhibitors: are we there yet?Len Neckers, Paul Workman
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
PI3 Kinase in Cancer: From Biology to ClinicPaul Workman, Paul Clarke
Chemistry & Biology|July 9, 2010
Probing the probes: fitness factors for small molecule toolsPaul Workman, Ian Collins
Nature Chemical Biology|November 17, 2006
New approaches to molecular cancer therapeuticsIan Collins, Paul Workman
Current Opinion in Pharmacology|September 2, 2014
Chemical biology approaches to target validation in cancerJulian Blagg, Paul Workman
Seminars in Oncology|September 25, 2016
Critical parameters in targeted drug development: the pharmacological audit trailUdai Banerji, Paul Workman
Pageof 32